Spots Global Cancer Trial Database for A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Official Title: A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Study ID: NCT01300533
Interventions
Study Description
Brief Summary: The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
Detailed Description: The study is designed to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of BIND-014 and define a recommended Phase 2 dose of BIND-014. All cycles of therapy will consist of the patient taking BIND-014 intravenously once every three weeks or weekly for three out of four weeks.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Investigational Site #01, Scottsdale, Arizona, United States
Investigational Site #02, Greenbrae, California, United States
Investigational Site #04, Los Angeles, California, United States
Investigational Site #06, Fort Meyers, Florida, United States
Investigational Site #03, Detriot, Michigan, United States
Investigational Site #05, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
